Table 4:
Cox proportional hazards analysis of overall survival for all 243 patients treated with FAS
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Variable | HR | 95% CI | P value | HR | 95% CI | P value |
| Age (>55 vs ≤55 years) | 1.44 | 1.06–1.94 | 0.018 | 1.49 | 1.1–2.03 | 0.01 |
| Sex (male vs female) | 0.91 | 0.68–1.23 | 0.58 | NS | ||
| Race (white vs other) | 1.37 | 0.83–2.27 | 0.22 | NS | ||
| Stage (metastatic vs locally advanced) | 0.74 | 0.42–1.31 | 0.30 | NS | ||
| Functional status (no vs yes) | 1.78 | 1.04–3.01 | 0.034 | 1.29 | 0.74–2.23 | 0.36 |
| Resected primary (yes vs no) | 0.81 | 0.57–1.15 | 0.25 | NS | ||
| Line of therapy (≥2nd line vs 1st line) | 1.82 | 1.21–2.74 | 0.004 | 1.65 | 1.08–2.52 | 0.02 |
| Chromogranin A (normal vs elevated) | 0.82 | 0.57–1.18 | 0.29 | NS | ||
HR: hazard ratio; CI: confidence interval